Indomethacin (IM) is an important indole acetic acid nonstiffness, prolonged duration of action, improved steroidal antiinflammatory drug commonly used in the bioavailability, patient compliance and reduction in treatment of rheumatoid arthritis and other severe adverse effects 9, 10 . Controlled release formulations can inflammatory diseases 1, 2 . IM is an inhibitor of PG synthesis provide convenient treatment regimens as compared to and used for several inflammatory orthopathies 3 , but in the conventional formulations 11, 12 . In the present recent years IM has also been recommended as the investigation indomethacin microspheres and capsule treatment of choice for low birth weight infants with were tested for in vitro dissolution. Further, comparative ductus arteriosus 4 . IM associated adverse effects are due bioavailability of indomethacin from microspheres and to initial high plasma concentrations 5 . The occurrence of capsule in healthy sheep was carried out. Plasma these adverse effects can be reduced by the use of concentrations of IM were quantified by a modification of controlled release formulations or by the concurrent administration of IM with probenacid 6, 7 . Oral conventional dosage forms are administered three to four times to maintain adequate and effective therapeutic concentration in blood, which is responsible for occurrence of high initial peak plasma concentrations. However it fails to protect the patients against morning stiffness 8 . Thus the development of controlled release formulations of IM have several advantages over the other conventional dosage forms, viz., reduction in occurrence of high initial peak plasma concentrations, protection against morning *For correspondence E-mail: dvg5@lycos.com the HPLC method described for IM by Johnson et al.
13

MATERIALS AND METHODS
IM and mefanamic acid (MA), the internal standards were generously donated by Micro labs (Bangalore, India). All other chemicals and solvents were of analytical grade and were supplied by Ranbaxy, fine chemicals (New Delhi, India). Formulations (Microcid ® SR 75 mg) and indomethacin loaded in cetostearyl alcohol microspheres are coded as product A and product B, respectively.
In vitro release and ageing studies:
In the present study, in vitro drug release profiles for www.ijpsonline.com products A and B were carried out using an USP XXI dissolution apparatus type II. Encapsulation of the microspheres was avoided, as dissolution of shell will add an additional parameter to the result. Dissolution studies were carried out for the formulation containing microspheres and compared with that of commercial formulation (Microcid SR ® -75 capsule) in 900 ml dissolution medium (2 h in pH 1.2 hydrochloric acid buffer and 6 h in pH 7.2 phosphate buffer). A small amount of Tween 80 (0.1%) was added to increase the wettability of microspheres. The dissolution media was occasions, separated by a wash out period of 2 w between dosing interval.
Blood sampling:
All the animals were reported to the pre-clinical trial laboratory from animal house at 7.00 a.m., after over night fasting of 10 h. After shaving near the neck region of sheeps, a 18 gauge (1.3×45 mm, 96 ml/min) cannula was inserted in to jugular vein and kept with heparinised saline lock for ensuing 24 h blood sampling. Test medication products A and B were maintained at 37° ± 0.5° and stirred at 100 rpm. Drug administered to the subjects with banana and 200 ml of release from the formulations were determined by water. A light food was provided at 3 h followed by withdrawing 10 ml of sample using guarded pipette at two standard meals at 7 and 11 h following the 30 min time intervals for first 4 h and at 1 h interval for administration of drug. Blood sample of 5 ml each was the remaining 4 h. Samples withdrawn were estimated collected at 0 h (pre-dose) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, after appropriate dilution. Release studies were carried 4, 5, 6, 7, 8, 12, 16, 20 , and 24 h post dose intervals. out in triplicate. The drug release from the products A The samples were centrifuged at 1500 'g' for 10 min, and B was calculated using standard drug release the plasma was separated and stored at -20° prior to equations and compared with that of commercially analysis. Any other type of food was not permitted available oral formulation, product A.
after 12 h after the administration of test medication. All subjects remained ambulatory and strenuous physical Effect of ageing on drug release studies were carried out activity was disallowed during the first 12 h of blood taking products A and B which were stored in a sampling. Plasma concentrations of drug from all the dessicator at 25º and 11% relative humidity for a period formulations and its corresponding commercial of 8 w. Each product (100 mg) was taken on the 1, 2, 4, formulation were quantified by a modified HPLC and 8 w and was subjected to in vitro drug release method as described by Johnson et al. 13 studies. Release studies were carried out in triplicate.
Statistical data analysis: In vivo studies:
The pharmacokinetic parameters were calculated using A written approval was obtained from the Institutional the Quick calk, computer PK calculation programme 14 Animal Ethical Committee of JSS Medical College Hospital The drug plasma concentration and pharmacokinetic and JSS College of Pharmacy, Mysore, India. Detailed parameters were subjected to paired t-test and analysis of verbal and written information on the study was provided variance at 95% confidence limit. to the Veterinary surgeon, in charge for Central Animal Facility, JSS Medical College Hospital and written consent
RESULTS AND DISCUSSION
was obtained. Four male and four female healthy adult . albino sheep were included in this study. The age of the sheep were in the range of 6-8 (7.13 ± 0.64 mean ± SD) y and their body weight ranged between 30-35 (31.87 ± 1.8 mean ± SD) kg. Based on medical history, examination, and laboratory investigation, none of the subjects had any medical abnormality. Provisions were made for all observed signs and symptoms occurring during the study period to be recorded.
Study design:
The study was conducted as an open, randomized complete cross over design in which a single 75 mg dose of each products (A and B) was administered to fasted, healthy adult male and female sheep on two different From the release studies, it was observed that, there was no significant release of drug at gastric pH. At the end of 8 h, drug release from products A and B at intestinal pH was found to be 94.80% and 99.41%, respectively. The cumulative percent drug release after ageing from products A and B was within the range (94%) and there was no significant change in the in vitro drug release was noticed after to 8 w of ageing.
The mean plasma concentration time profiles and comparative mean pharmacokinetic parameters of indomethacin following the administration of the two products (A and B) are shown in fig. 1 www.ijpsonline.com observed for product A (2054 ± 55.78 ng/ml) compared to product B (1929 ± 20.32 ng/ml. However, the difference in values recorded for both products was statistically insignificant. The peak plasma levels were However, a small difference between both products related to C max, T max, T 1/2 and reduced fluctuations (peak to trough ratios) of the plasma concentrations. All these effects probably may be due to the dissolution rate limited drug release and hence absorption 16 . From the study it can be observed that reduced fluctuations combined with the elevated mean plasma concentration from both the products, offers advantage in protecting patients against morning stiffness.
Mean residence time (MRT) of products A and B was found to be 4.76 ± 0.10 h and 4.98 ± 0.02 h, respectively. The difference in mean values of MRT from the two formulations was statistically insignificant.
The mean AUC 0-24 values for products A and B was 9637 ± 132.87 ng h/ml and 8343 ± 40.04 ng h/ml. From the result, statistical analysis indicated that the product B exhibited a smaller and non-significant reduction in the AUC values. It was observed that the slow release of IM from the products A and B may be responsible for the decreased AUC values when compared to the reported conventional dosage forms 17 . The observed mean AUC values for products A and B was 9870 ± 129.22 ng h/ml and 8617 ± 46.88 ng h/ml does not show any significant statistical difference between the products. observed to be within the range from 1978 ng/ml to 2086 ng/ml for product A, from 1912 ng/ml to 1955 ng/m for product B. Comparison of the mean concentration time curve of product A with that of product B, indicates that the product B associated with a significant lower peak plasma concentration than that of product A. In addition, the mean plasma concentrations of IM for both the products in all subjects were within the therapeutic window (300-3000 ng/ml) 15 . The time taken to reach peak plasma concentration T max was 3.5 and 3 h for products B and A, respectively. T max of IM was little higher in case of product B, but no statistical significant difference was found between two products. Mean K a for product A product B were found to be 0.3812 ± 0.002 h -1 and
The individual and mean AUC 0-24 ratios (B/A), reflects the relative extent of absorption of product B with that of product A is presented in Table 2 . The average values of the individual and mean AUC ratio at 95% 0-24 confidence limit, was within acceptable limits for bioequivalent products 18 .
To obtain in vitro-in vivo correlation, absorption profiles were constructed for product A and B using the fraction absorbed in vivo was plotted against fraction dissolved in vitro is shown in fig. 2 (A and B) . It was observed that the both products showed an adequate correlation www.ijpsonline.com Relative bioavailability (AUC ratio) of product B to product A administered orally (75 mg) as controlled release products. Mean ± SD subjects very well tolerated them. These findings clearly shown that the absence of high peak concentrations (>5000 ng/ml), which are very often associated with adverse effects 5 , which was reported due to accumulation effect. The products A and B included in this study were found to be bioequivalent. 
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